Cupid Limited experienced a 2.21% decline on Friday, May 15, 2026, falling from ₹123.08 to ₹120.36. During the trading session, the stock fluctuated between a day low of ₹119.43 and a day high of ₹124.70, representing a 4.41% intraday movement. Trading volume decreased by 201 thousand shares on the last day, with total trading volume of approximately ₹1.34 billion across 11 million shares. The stock has shown mixed performance with a 0.65% gain over the past two weeks, though it has declined in 4 of the last 10 trading days. According to technical analysis, the stock is currently in a horizontal trend with a 90% probability to trade between ₹74.32 and ₹401.54 over the next 3 months, presenting a potential buying opportunity despite recent weakness.
Cupid, a contraceptives manufacturer, has delivered an extraordinary 620% rally over the past year, making it the most expensive stock in its category with a trailing-twelve-month P/E ratio of 197. The stock has demonstrated remarkable resilience, remaining unaffected by domestic and external challenges including foreign outflows, falling rupee, and volatile market conditions. As per The Economic Times, the stock has surged over 4,500% in the last three years, showcasing its exceptional long-term performance trajectory. The stock is currently trading above its 50-day and 200-day simple moving averages of ₹98 and ₹70 respectively, with a one-year beta of 0.7 in a volatile market environment.
The company's financial performance has been robust, with net profit surging 200% year-on-year to ₹33 crore in Q3 FY26 compared to ₹11 crore in the corresponding quarter of the previous financial year. As reported by The Economic Times, sales soared 103% to ₹104 crore versus ₹51 crore in the same quarter last year. The company has reported sequential growth in profit after tax and revenue from operations for the past six quarters. In its quarterly update on March 31, Cupid guided that it will comfortably surpass its FY26 annual guidance of ₹335 crore revenue and ₹100 crore net profit, with expectations of achieving ₹600 crore revenue in FY27 and net profit margin in excess of 30%. The company is yet to announce its Q4 earnings, but its Q3 performance demonstrates strong execution capabilities and improving operating leverage.
According to Nitant Darekar, Research Analyst at Bonanza, Cupid has evolved from a pure condom exporter to a three-engine business model. As reported by The Economic Times, the company now operates a high-margin B2B export business accounting for 90% of revenue, backed by WHO/UNFPA prequalification and entries into 125 countries. The domestic FMCG portfolio is scaling rapidly, while an emerging IVD diagnostics vertical is targeting 4x capacity by end-2026. The Palava facility ramp-up, GCC and Saudi FMCG plans, and a record order book provide multi-year visibility for sustained growth. Darekar notes that "What was once a pure condom exporter is now a three-engine play" with "strong earnings, multi-year growth visibility and a fast-scaling FMCG portfolio."
Despite strong fundamentals, experts are advising caution due to the stock's high valuation. According to The Economic Times, FMCG peer comparison data shows Procter & Gamble Hygiene and Health Care, Gillette India, Emami, Honasa Consumer, Bajaj Consumer Care and Anondita Medicare have P/Es ranging from 23.18 to 70.78. Nilesh Jain, Vice President at Centrum Finverse, notes that while Cupid is in a secular uptrend with a target of ₹135+ levels, the risk and reward ratio is not favorable for fresh buying. He recommends avoiding fresh purchases and suggests investors remain invested with a trail stop loss near the support level of ₹110. The stock's current valuation at 197 P/E significantly exceeds the peer group average, raising concerns about the sustainability of current price levels given the company's strong but not exceptional growth trajectory.
